Ethyl-Hexedrone

This article requires proofreading. As such, it likely contains incorrect grammar, spelling, and punctuation.

Ethyl-Hexedrone
Chemical Nomenclature
Common names	Ethyl-Hexedrone, HEX-EN
Systematic name	2-(ethylamino)-1-phenylhexan-1-one
Routes of Administration
Insufflated Dosage WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section. DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation. This dosage and duration information has been sourced from the personal experience of PsychonautWiki users. Threshold 5 - 15 mg Light 15 - 30 mg Common 30 - 40 mg Strong 40 - 50 mg Heavy 50 mg + Duration Total 1 - 4 hours Onset 15 - 30 minutes

Ethyl-hexedrone (also known as n-ethyl-hexedrone and hexen) is a stimulant research chemical belonging to the cathinone group. Ethyl-hexedrone's stimulation is believed to be caused by its affinity as an NDRI (norepinephrine-dopamine reuptake inhibitor); however, there have been no scientific studies confirming this.

Ethyl-hexedrone is closely related to hexedrone, with an added ethyl-group on the carbon chain containing the nitrogen. This addition makes it about 3x as potent as hexedrone.

Ethyl-hexedrone was first synthesized in 2011, but became known in the research chemical market during late 2015. Little research exists about ethyl-hexedrone and its parent compound hexedrone. All dosage information found on the internet should be treated with caution.

This chemistry section is incomplete. You can help by adding to it.

Ethyl-hexedrone is a substituted cathinone, which means that it features a phenethylamine core with an alkyl group attached to the alpha carbon and a ketone group attached to the beta carbon.

Ethyl-hexedrone can be compared to the much better known pentedrone. Hexedrone is a chain extended version of pentedrone. Extension of the carbon chain usually results in less potency. However, the addition of the ethyl group to hexedrone increases its potency significantly. This also leads to the conclusion that ethyl-pentedrone would result in an even more potent chemical.

Due to the lack of research regarding the substance, all discussion regarding the pharmacology of it is purely based upon its structure and subjective effect similarities to other cathinones such as mephedrone and others. 2-AI most likely acts as both a dopamine and norepinephrine releasing agent or reuptake inhibitor. This allows dopamine and norepinephrine to accumulate within the brain, resulting in stimulating and euphoric effects.

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.

Physical effects

• Spontaneous tactile sensations - High doses of ethyl-hexedrone result in a pleasurable body high characterized by pleasant tingling.
• Stimulation - In terms of its effects on the user's physical energy levels, ethyl-hexedrone can be considered to be extremely stimulating and energetic.
• Dehydration - Dry mouth and increased sweating can occur after consuming ethyl-hexedrone. Low doses of the substance in question cause minimal dehydration.
• Vasoconstriction - Ethyl-hexedrone can be considered slightly vasoconstricting.
• Tactile enhancement
• Increased heart rate
• Increased perspiration
• Appetite suppression
• Focus enhancement
• Temporary erectile dysfunction
• Increased blood pressure
• Teeth grinding - This component can be considered to be less intense when compared with that of MDMA.

Cognitive effects

• Euphoria
• Thought acceleration
• Analysis enhancement - This effect is mostly present in lower doses when not overshadowed by euphoria.
• Immersion enhancement
• Time distortion
• Ego inflation
• Disinhibition
• Motivation enhancement
• Compulsive redosing

After effects

The effects which occur during the offset of a stimulant experience generally feel negative and uncomfortable in comparison to the effects which occurred during its peak. This is often referred to as a "comedown" and occurs because of neurotransmitter depletion. Its effects commonly include:

• Cognitive fatigue
• Thought deceleration
• Anxiety
• Depression
• Wakefulness
• Irritability

The toxicity and long-term health effects of recreational Ethyl-Hexedrone use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because Ethyl-Hexedrone has very little history of human usage. Anecdotal evidence from people who have tried Ethyl-Hexedrone within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed).

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

As with other stimulants, the chronic use of Ethyl-Hexedrone can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of Ethyl-Hexedrone develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). Ethyl-Hexedrone presents cross-tolerance with all dopaminergic stimulants, meaning that after the consumption of Ethyl-Hexedrone all stimulants will have a reduced effect.

Psychosis

Abuse of compounds within the stimulant class at high dosages for prolonged periods of time can potentially result in a stimulant psychosis that may present with a variety of symptoms (e.g., paranoia, hallucinations, or delusions).^[1] A review on treatment for amphetamine, dextroamphetamine, and methamphetamine abuse-induced psychosis states that about 5–15% of users fail to recover completely.^[2][3] The same review asserts that, based upon at least one trial, antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis.^[4]

Dangerous interactions

Although many drugs are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

• Stimulants - Ethyl-Hexedrone can be potentially dangerous in combination with other stimulants as it can increase one's heart rate and blood pressure to dangerous levels.
• 25x-NBOMe - Both the NBOMe series and this compound induce powerful stimulation and their interaction may cause severe side effects. These can include thought loops, seizures, increased blood pressure, vasoconstriction, increased heart rate, and heart failure (in extreme cases).
• Alcohol - It is dangerous to combine alcohol, a depressant, with stimulants due to the risk of excessive intoxication. Stimulants decrease the sedative effect of alcohol which is the main factor most people consider when determining their level of intoxication. Once the stimulant wears off, the effects of alcohol will be significantly increased, leading to intensified disinhibition as well as respiratory depression. If combined, one should strictly limit themselves to only drinking a certain amount of alcohol per hour.
• DXM - This combination may cause increased heart rate and panic attacks.
• MXE - Increased heart rate and blood pressure may occur.
• Tramadol - This combination can increase the risk of seizures.
• MDMA - The neurotoxic effects of MDMA may be increased when combined with amphetamine and other stimulants.
• MAOIs - This combination may increase the amount of neurotransmitters such as dopamine to dangerous or even fatal levels. Examples include syrian rue, banisteriopsis caapi, 2C-T-2, 2C-T-7, αMT, and some antidepressants.^[5]
• Cocaine - This combination may increase strain on the heart.

This legality section is a stub. As such, it likely contains incomplete or wrong information. You can help by expanding it.

• United Kingdom - It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.^[6]

• Responsible use
• Stimulant
• Cathinone

1. ↑ Treatment for amphetamine psychosis | [1]
2. ↑ Treatment for amphetamine psychosis | [2]
3. ↑ Hofmann FG (1983). A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects (2nd ed.). New York: Oxford University Press. p. 329. ISBN 9780195030570.
4. ↑ Treatment for amphetamine psychosis | [3]
5. ↑ Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity | http://bja.oxfordjournals.org/content/95/4/434
6. ↑ Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted